Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2024-10-02

Clinical Trial Update: Safety and Efficacy of AR1005 in Patients with Lewy Body Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AR1005 for safety and efficacy in Lewy body dementia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AR1005

Snippet

Sponsor: Yonsei University | Conditions: Lewy Body Dementia | Phase 2 | Status: RECRUITING